The International Society for Vaccines is an organization that engages, supports, and sustains the professional goals of a diverse membership in all areas relevant to vaccines - 2017 ISV Annual Congress

2018 President's Letter

Dr WeinerHappy 2018! As we welcome in the New Year, we recognize that this is a dynamic and important time for ISV presenting a slew of novel challenges and opportunities for the vaccine field. Old paradigms are rapidly being reworked with virtually no area of vaccine research, vaccine development, clinical trials, vaccine deployment or policy left untouched. In just the last 6 years the EID outbreaks of MERS, Ebola, Zika, CHIKV as examples have underscored the importance of rapid vaccine development and deployment capabilities to meet EID challenges, as well as growing appreciation for creativity and flexibility in clinical trial design. Novel and important new partners have emerged in this space. The creation of CEPI (The Coalition for Epidemic Preparedness Innovations) and the announcement of the new Gates Medical Research Institute underscore that new approaches for both old and new ID foes will be tackled with a focus on creativity and innovation that will challenge and influence the vaccine field in diverse ways. The footprint of vaccine research has increased. Concepts of how to apply vaccines as part of cancer treatment or as prevention of recurrence, are moving vaccines from being considered a secondary player in cancer clinical management to vaccine approaches gravitating towards becoming a central plank in the newest area of cancer therapy research. In 2018, the very definition of what is a vaccine and how vaccines are deployed in therapy and prevention continues to be refined.

It is important to consider as we face these opportunities that ISV has never been stronger and more capable of lending a hand. All members of ISV should be proud that the energy and accomplishments of our members and our leadership over the past few years have increased our voice, solidified our society and put us in a strong financial position. We are very much in debt to all of you who have brought us to where we are today. We are building from the excitement and accomplishment of the highly successful ISV 2017 meeting held in Paris last October. This meeting was organized in partnership with the Institute Pasteur, which provided the Institute itself as the historic backdrop for the many ISV sessions. ISV prides itself on serving as a society that lifts all boats in the vaccine space and the 2017 meeting displayed the vitality, and innovation and diversity of topics and exciting panel discussions, illustrative of the central tenets of ISV. We are excited to now move back across the ocean to Atlanta, which will be the site of the 2018 annual meeting. Once again local partners will play a major role the 2018 meeting. More information will be forthcoming on the ISV website and in the ISV newsletter so please stay tuned.

Continue Reading

Julius S. Youngner, Sc.D., Polio Vaccine Pioneer and 2015 ISV Fellow, Dies at 96 years of age.

Julius S. Youngner, Sc.D., a world-renowned virologist best known for his contributions to the development of the first effective polio vaccine alongside Jonas Salk, died peacefully Thursday, April 27, 2017 at his home in Pittsburgh, surrounded by family.  Dr. Youngner, a Distinguished Service Professor Emeritus of microbiology and medical genetics at the University of Pittsburgh School of Medicine, had a remarkable scientific career that spanned more than 60 years, influenced the careers of an entire generation of virologists, and has saved innumerable lives. More info here.

ISV collaboration vaccine conferences 

Educational Activities